TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025 ...

Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization ... (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive ...

RevolKa will create and deliver highly functional proteins, in collaboration with Daiichi Sankyo Co., Ltd. by using its proprietary protein engineering platform technology, called aiProtein®: a ...

Daiichi Sankyo Co. will seek to maintain its edge over competitors in precision cancer ... its President and Chief Operating Officer Hiroyuki Okuzawa told Bloomberg News on Friday in ...

Now that Enhertu — their breast cancer drug that is on track to generate over $10 billion annually — is a proven global success, Daiichi Sankyo does not want to share other future complex ...